These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 17616356

  • 1. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy.
    Fujisawa T, Ikegami H, Noso S, Hiromine Y, Kawabata Y, Nishino M, Asano K, Ogihara T.
    J Diabetes Complications; 2007; 21(4):252-7. PubMed ID: 17616356
    [Abstract] [Full Text] [Related]

  • 2. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T.
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [Abstract] [Full Text] [Related]

  • 3. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H, Ando K, Ueshima K, Babazono T, Kario K, Tanaka S, Nakao K, Fujita T, SAKURA Trial Investigators.
    Clin Exp Hypertens; 2011 Apr; 33(7):455-62. PubMed ID: 21649534
    [Abstract] [Full Text] [Related]

  • 4. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, Ogihara T.
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [Abstract] [Full Text] [Related]

  • 5. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
    Masuda T, Ogura MN, Moriya T, Takahira N, Matsumoto T, Kutsuna T, Hara M, Aiba N, Noda C, Izumi T.
    Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
    [Abstract] [Full Text] [Related]

  • 6. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
    Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Crepaldi G.
    Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Ando K, Ueshima K, Tanaka S, Kosugi S, Sato T, Matsuoka H, Nakao K, Fujita T.
    Int J Med Sci; 2013 Oct; 10(9):1209-16. PubMed ID: 23935398
    [Abstract] [Full Text] [Related]

  • 8. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K, Wakatsuki T, Orino S, Kawano K, Sata M.
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Ito S.
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [Abstract] [Full Text] [Related]

  • 10. Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive type 2 diabetic patients with microalbuminuria.
    Deerochanawong C, Kornthong P, Phongwiratchai S, Serirat S.
    J Med Assoc Thai; 2001 Feb; 84(2):234-41. PubMed ID: 11336083
    [Abstract] [Full Text] [Related]

  • 11. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Fukumoto S, Ishimura E, Motoyama K, Morioka T, Kimoto E, Wakikawa K, Shoji S, Koyama H, Shoji T, Emoto M, Nishizawa Y, Inaba M, Cilnidipine vs L-type calcium channel blockers Evaluation of Antihypertensive Renoprotective Effects in Diabetic patients (CLEARED) Study Investigators.
    Diabetes Res Clin Pract; 2012 Jul; 97(1):91-8. PubMed ID: 22336632
    [Abstract] [Full Text] [Related]

  • 12. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S, Yano Y, Maki K, Iwasaka T.
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [Abstract] [Full Text] [Related]

  • 13. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
    Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K.
    Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
    [Abstract] [Full Text] [Related]

  • 14. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T.
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [Abstract] [Full Text] [Related]

  • 15. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 16. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.
    Takahara A.
    Cardiovasc Ther; 2009 Nov; 27(2):124-39. PubMed ID: 19426250
    [Abstract] [Full Text] [Related]

  • 17. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [Abstract] [Full Text] [Related]

  • 18. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.
    Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, Nitta K.
    Am J Nephrol; 2009 Jun; 30(2):155-61. PubMed ID: 19325231
    [Abstract] [Full Text] [Related]

  • 19. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
    Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M.
    Hypertens Res; 2011 Feb; 34(2):268-73. PubMed ID: 21124330
    [Abstract] [Full Text] [Related]

  • 20. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T, Oka K, Ueda H, Imai E.
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.